Business Wire

Toshiba’s New Simulation Technology for Model-Based Development Shortens Verification Times for Automotive Semiconductors by About 90 Percent

21.9.2021 07:50:00 EEST | Business Wire | Press release

Share

Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has developed a model-based development (MBD) simulation technology that shortens verification times for automotive semiconductors by about 90 percent.[1] The technology allows automotive equipment developers to quickly evaluate designs using Toshiba’s automotive semiconductors, helping to shorten development times.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005989/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Simulation results with the new technology (Graphic: Business Wire)

As electric vehicles grow in popularity and advanced driver-assistance systems become standard, automotive equipment is growing increasingly advanced and complicated. Model-based development, a development methodology that uses software to simulate models and evaluate performance in real-time, is helping product developers to refine complex design processes. In the automobile industry, MBD contributes to development advances by simultaneously progressing design and verification prior to making prototypes.

MBD separates functions into blocks and verifies total vehicle behavior by connecting each block. Detailed simulation models that include the behavior of semiconductors in individual blocks are required to verify heat and electromagnetic interference (EMI), essential parameters for assessing the performance of automotive equipment. However, as models become more detailed and precise, verification times are growing longer.

Toshiba took a long hard look at its current evaluation and verification technology for automotive equipment. Sub-systems like electric power steering comprise semiconductor-based electronic circuits that work in microseconds along with mechanical components, gears and shafts, that work in milliseconds. Toshiba’s current technology simulates the electronic circuits and mechanical components at the same time, on a microsecond basis, but this results in a large number of unnecessary and time-consuming calculations in the mechanical components. The technology is also complicated because it adopts the SPICE model—Simulation Program with Integrated Circuit Emphasis—that defines over 100 parameters for the simulation of semiconductor behavior.

Toshiba’s new modeling technology, “Accu-ROMTM”, separately calculates the electronic circuits and the mechanical components. First it verifies the mechanical components, then simplifies the model for mechanical components and finally verifies the total system, including its electric circuits. This approach eliminates unnecessary calculations. In evaluating the electric circuits, the model automatically generates a Very High speed integrated circuit Hardware Description Language-Analog Mixed Signal (VHDL-AMS) model from the SPICE model. VHDL-AMS model allows the verification range to be limited to essential parameters, such as heat and EMI noise, shortening the verification time. For example, verification of a power steering system with Toshiba’s current technology takes 32 hours 51 minutes, but that falls to 3 hours 27 minutes[1] with the new technology.

Toshiba will use the new technology to promote development of high-heat dissipation and low noise automotive semiconductors, and to provide its customers with a development environment which makes it easier to use Toshiba’s products. In addition to automotive applications, Toshiba will use the new technology in semiconductors for other applications, such as industrial equipment and home appliances.

Notes
[1] Verification times for simulation of three-phase inverter circuits in an automotive electric power steering system during a right turn with a duration of six seconds.

* Accu-ROM™ is a trademark of Toshiba Electronic Device & Storage Corporation.
* All other company names, product names and service names may be trademarks of their respective companies.

About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation, a leading supplier of advanced semiconductor and storage solutions, draws on over half a century of experience and innovation to offer customers and business partners outstanding discrete semiconductors, system LSIs and HDD products.
The company's 22,000 employees around the world share a determination to maximize product value, and promote close collaboration with customers in the co-creation of value and new markets. With annual sales now surpassing 710-billion yen (US$6.5 billion), Toshiba Electronic Devices & Storage Corporation looks forward to building and to contributing to a better future for people everywhere.
Find out more at https://toshiba.semicon-storage.com/ap-en/top.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Motohiro Ajioka
Corporate Communications & Market Intelligence Group
Business Planning Div.
Toshiba Electronic Devices & Storage Corporation
semicon-NR-mailbox@ml.toshiba.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye